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Introduction {#s1}
============

Inorganic arsenic (iAs) is a ubiquitously distributed environmental and industrial toxicant, classified as a class I carcinogen by the International Agency for Research on Cancer ([@c24]). More than 137 million people in more than 70 countries are exposed to iAs at levels of greater than $0.13\;\mu M$ ($10\text{ ppb}$) ([@c48]), which is the drinking water standard mandated by the U.S. Environmental Protection Agency (U.S. EPA) ([@c8]; [@c42]). Of particular concern, growing epidemiological evidence reveals adverse health effects at lower iAs levels (iAs level of well water $< 50\text{ ppb}$) than previously realized ([@c8]; [@c52]). Epidemiological studies and experimental evidence link chronic iAs exposure with increased risk of certain cancers ([@c65]) and multiple noncancerous adverse health conditions ([@c8]; [@c42]; [@c65]). Although not conclusive, emerging epidemiological data suggest a direct causal relationship between iAs exposure and prostate cancer incidence and mortality ([@c5]; [@c9]; [@c65]); however, the precise mechanisms underlying this iAs-induced tumorigenesis remain unclear.

Properties of adult stem-progenitor cells make them compelling targets of tumorigenesis ([@c7]; [@c75]). Indeed, transcriptomic analysis has shown that basal stem cell signatures are enriched in metastatic prostate cancer ([@c55]). Environmental factors play an important role in cancer etiology ([@c65]; [@c75]), and prostate stem-progenitor cells (PrSPCs) are hormone (e.g., estrogen and bisphenol A) targets associated with prostate cancer susceptibility ([@c43]). Epidemiological studies indicate prenatal arsenic exposure is linked with increased mortality risks related to cancer and noncancer diseases ([@c2]), suggesting that arsenic may target the long-lived stem cell population. Further, experimental findings revealed that iAs can directly alter neural, skin, and prostate stem cells, shifting their differentiation capability and augmenting transformation ([@c8]; [@c65]). These observations are highly significant because recent evidence suggests that cancer may originate from transformation of resident tissue stem cells that self-renew and differentiate into abnormal progeny that continuously seed tumor growth ([@c7]; [@c75]). Previous studies by Waalkes et al. interrogated iAs-driven prostate carcinogenesis using an immortalized benign human prostate epithelial cell line (RWPE-1 cells) and its stem-progenitor cell-line derivative, WPE cells, finding that extended *in vitro* exposure to $5\;\mu M$ iAs transformed the cells which, upon transplantation in mice, formed malignant, poorly differentiated tumors ([@c63]). Although these studies yield significant mechanistic insights, the HPV-18 immortalized RWPE-1 cells are primed for transformation and can form low-grade tumors *in vivo* without secondary hits ([@c80]). As such, it remains to be determined whether a range of iAs doses can transform the normal human prostate stem and progenitor cell populations.

Autophagy is a conserved, tightly regulated process with an essential role in protein and organelle quality control through capture, degradation, and recycling of intracellular proteins and organelles ([@c38]). It is noteworthy that stem cells, including PrSPCs ([@c19]), have elevated autophagic activity relative to daughter progenitor cells and differentiated cells, and this heightened autophagic capability was critical for long-term survival ([@c17]; [@c36]). Although autophagy suppresses initiation of tumors, it can also facilitate progression of established tumors ([@c1]; [@c28]; [@c74]). Of significance, arsenic exposures have been shown to affect autophagy in a cell- and dose-dependent manner ([@c45]). Although the mechanistic underpinnings remain elusive, many consider autophagy to be a cellular protective mechanism against arsenic-related tumorigenesis ([@c29]; [@c45]). Recently, arsenic was shown to block autophagic flux in a variety of mouse and human cell lines, leading to persistent Kelch-like ECH-associated protein 1 (KEAP1)-NRF2 pathway activation *in vitro* ([@c29]; [@c45]). However, the same has not been determined for stem-progenitor cells in any system or with prostate carcinogenesis. It is interesting that, similar to autophagy, NRF2 is a tumor suppressor in normal cells but also plays an oncogenic role in aggressive tumor cells ([@c26]; [@c56]).

The present study sought to address previously unresolved issues regarding iAs-induced prostate carcinogenesis by using primary prostate epithelial cells (PrECs) from young organ donors to first determine whether iAs exposure at environmentally relevant levels disturbs normal stem-progenitor cell homeostasis and whether this may be capable of transformation of this long-lived population. Current U.S. EPA guidelines indicate a maximum allowable level for arsenic in drinking water of $0.13\;\mu M$ ($10\text{ ppb}$; $10\;\mu g/L$) (<https://www.epa.gov/dwreginfo/chemical-contaminant-rules>) ([@c8]; [@c42]), although levels may reach $50–500\;\mu M$ ($3.8–38\text{ ppm}$; $3.8–38\;{mg}/L$) in contaminated groundwater ([@c49]). As such, we first assessed responses to $0–50\;\mu M$ iAs to embody a full range of chronic arsenic exposure levels. Next, we sought to determine the molecular underpinnings of observed alterations in the PrSPCs by combining transcriptomic analysis with functional assays including an *in vivo* chimeric prostate model. The data led to the interrogation of the KEAP1-NRF2 pathway and the autophagy status within the PrSPC population as a function of iAs exposure.

Materials and Methods {#s2}
=====================

Reagents and Antibodies {#s2.1}
-----------------------

Sodium arsenate solution (VWR, 3; Cat. No. 5000-1L) was used as the source of iAs for all the studies. The following reagents were used: LysoHunt Red DND-99 (Setareh Biotech; Cat. No. 7522), Oltipraz (Sigma, Cat. No. O9389), N-acetyl-L-cysteine (Sigma, Cat. No. A9165), Sea Plague low-melt agarose (Lonza; Cat. No. 50101), BafA1 (Sigma, Cat. No. B1793), and chloroquine (Sigma, Cat. No. C6628). The information of the antibodies is included in Table S2, including source, identifier, and dilution for immunoblotting (IB) and immunofluorescence (IF).

Cell Culture and Treatment {#s2.2}
--------------------------

Primary human PrECs were obtained from 4 young (19--21 y old) disease-free donors (Lifeline® Cell Technology) and cultured in Prostalife™ Epithelial Medium (Lifeline® Cell Technology; Cat. No. LL-0041), as previously described ([@c21]). Cells from passages 3--8 were used. RWPE1 cells were obtained from ATCC and cultured in Keratinocyte Serum-Free Medium (KSFM; ThermoFisher Scientific; Cat. No. 17005042). Cells from passages 5--20 were used. Embedded prostasphere (PS) culture was conducted as previously described with Prostalife™ medium ([@c21], [@c18]). Briefly, for each well of a 12-well plate, 50,000--100,000 cells were suspended in $0.5\text{ mL}$ ice-cold 1:1 mixture of culture medium and Matrigel® (Corning®; Cat. No. 356231) on ice. They were then seeded around the bottom rim of the well using pipette transfer, and the mixture was solidified by incubating at 37°C for 30 mins. Warm medium ($1\text{ mL}$ at 37°C) was added over the Matrigel® slurry and changed every 2--3 d over a 5- to14-d culture period. For ultralow-attachment PS cultures, 1,000--2,000 dissociated cells were resuspended in $200\;\mu L$ Prostalife™ medium with 5% Matrigel®, seeded to wells of 96-well plate (Corning®; Cat. No. 3474), and cultured for 1 wk without change of medium.

Prostate organoid (PO) culture derived from primary human PrECs is similar to embedded PS culture but uses a different medium to drive epithelial differentiation. PO medium used was a modification of previously described ([@c11]) human PO medium, a medium using FBS and testosterone to drive differentiation *in vitro.* The final PO medium was KSFM with 5% charcoal-stripped FBS (ThermoFisher Scientific; Cat. No. 12676), $1\;\mu M$ Y-27632 dihydrochloride (Abmole Bioscience; Cat. No. M1817), and $10\text{ nM}$ DHT (Sigma; Cat. No. A-8380).

To retrieve PS and PO from embedded cultures, the Matrigel® mixture was digested with Dispase® (Stemcell Technologies; Cat. No. 07913). Briefly, Dispase® was added to the Matrigel® mixture containing PS or PO ($\text{volume\ of\ mixture}:\text{dispase} = 1:2$), mixed thoroughly by pipetting up and down several times, incubated at 37°C for 30 mins, and centrifuged at $800\; g$ for 5 min to collect a PS or PO pellet. For iAs exposure, commercially available sodium arsenate solution (VWR, $5000–1L$; $50\text{ mM}$) was diluted with water of cell culture grade to make 1000× stock solution, which was stored at 4°C before adding to the cell culture medium directly at the stated final concentration.

Bromodeoxyuridine (BrdU)-Label Retention Assay {#s2.3}
----------------------------------------------

Parental PrEC were 2D cultured with $1\;\mu M$ BrdU (Sigma-Aldrich) for 10 d for labeling of dividing cells as previously described ([@c19], [@c18]). Cells were transferred to 3D Matrigel® culture for 7 d to permit BrdU wash-out during spheroid growth ($\sim 6\;\text{cell\ cycles}$). PS were harvested by Dispase® digestion and attached to chamber slides during overnight culture in Prostalife™ culture medium. Spheres were fixed in ice-cold methanol at $- 20ºC$ for 20 min; BrdU epitopes were exposed by incubation with $2M$ HCl at room temperature (RT) for 30 min and then washed 3 times with PBS before immunostaining using mouse anti-BrdU antibody.

Immunoblotting {#s2.4}
--------------

Cell lysates were prepared in cell lysis buffer (Cell Signaling Technology; Cat. No. 9803). Protein loading was standardized with a BCA assay (ThermoFisher Scientific; Cat. No. 23225). Total protein ($10–50\;\mu g$) from each sample was resolved on 10% or 15% SDS-PAGE gels and transferred to PVDF membranes (Bio-Rad; Cat. No. 162-0177). Membranes were blocked with 5% nonfat dry milk in TBST buffer ($20\text{ mM}$ Tris base, $50\text{ mM}$ NaCl, $2.5\text{ mM}$ EDTA, 0.1% Tween-20, pH 7.5) for 30 min at RT and then incubated with primary antibodies diluted in 5% nonfat dry milk in TBST at 4°C overnight. After washing with TBST ($3 \times 5\text{ min}$ min, RT), membranes were incubated with appropriate horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology; Cat. Nos. 7074 and 7076) and developed using ECL or ECL-Plus on Biomax MR film (Kodak). Integrated band densities were quantified using ImageJ software (<https://imagej.nih.gov/ij/>).

Immunostaining {#s2.5}
--------------

Immunostaining was conducted as previously described ([@c21], [@c19], [@c18]; [@c47]). Briefly, PS or PO were attached overnight on chamber slides (Millipore Sigma; Cat. No. PE2GS0416) to permit limited cell outgrowth and improve reagent penetration. Cell culture samples on slides were washed with PBS, then fixed with 5% paraformaldehyde (PFA) at RT for 20 min, permeabilized by incubating with 0.5% Triton X-100 at RT for 5 min. Sample slides were blocked with 5% normal goat serum in PBS with 0.25% Triton X-100 for 30 min at RT, then incubated with primary antibody diluted with incubating buffer (PBS with 2% normal goat serum and 0.125% Triton X-100) overnight at 4°C. After washing (PBS, $3 \times 5\text{ min}$ at RT), slides were incubated in the dark with secondary antibody diluted with incubating buffer at RT for 1 h. After washing, sample slides were mounted for imaging. For animal tissues, samples were fixed in acetone and methanol (1:1) overnight at 4°C, and then incubated in 70% ethanol overnight at 4°C, followed by a regular immunohistochemistry procedure of processing, embedding, and section. For antigen retrieval, tissue sections of $4\;\mu M$ were heat-treated for antigen retrieval in a Decloaker pressure cooker (Biocare Medical) in Tris-EDTA, pH 9.0 buffer for 3 min. Then, tissue slides were immunostained as described above. The dilution factor of antibodies is included in Table S2. Stained slides were imaged with a Zeiss Axioskop 20 fluorescent microscope and Axio camera.

Hoechst Exclusion Assay {#s2.6}
-----------------------

The Hoechst exclusion assay was performed as previously described ([@c20]; [@c43]) to assess the stem-like cells in 2D-cultured cells. PrEC cells were preincubated for 10 min with or without $50\;\mu M$ verapamil hydrochloride (Sigma-Aldrich; Cat. No. V4620-1G), which inhibits ABCG2 transporter protein expressed at high levels in stem cells, blocking their Hoechst exclusion ability. Cells were next incubated in $0.5\;\mu g/\text{mL}$ Hoechst 33342 (Sigma-Aldrich; Cat. No. B2261) in Hank's balance salt solution, 10% FBS, 1% D-glucose, and $20\text{ mM}$ HEPES for 30 min at 37°C, washed in PBS and incubated with $1\;\mu g/\text{mL}$ Propidium iodide (PI) (Sigma-Aldrich; Cat. No. P4170-10MG) for dead cell exclusion. Hoechst-stained cells were separated by single-channel FACS (CyAnTM ADP Analyzer). All results were confirmed by side-population double-channel FACS analysis (Beckman Coulter; MoFloTM XDP analyzer) using $5\;\mu g/\text{mL}$ Hoechst dye. The percent prostate stem-like cells were calculated as the difference in Hoechst excluding cells incubated $- / +$ (with or without) verapamil.

Transcriptome Analysis {#s2.7}
----------------------

Total RNA was extracted from PS and PO cultured $- / +$ $1\;\mu M$ iAs for 2 wk ($n = 3$ for each group; total 12 samples) with the same RNA isolation method described below for real-time PCR analysis. Microarray analysis with the Illumina HumanHT12 V4 Gene Expression Microarray were performed according to the standard protocol at the University of Chicago Genomics Facility. Raw data are available at Gene Expression Omnibus (GSE137357). Differentially expressed genes (DEG) with iAs exposures were identified by Limma R package (Limma v3.28.14; R v3.2.4) with a cutoff of fold change $> 1.5$ and $p$-value $< 0.05$ ([@c51]), which is provided as Table S3. Enriched pathways for DEG were identified by Wikipathway Analysis on WEB-based GEne SeT AnaLysis Toolkit (WebGestalt 2017; <http://www.webgestalt.org/2017/option.php>) ([@c69]) and GSEA software (v3.0) ([@c59]).

Quantitative Real-Time PCR Analysis {#s2.8}
-----------------------------------

For total RNA isolation, PS/PO samples from wells of 12-well plates were collected from Matrigel® cultures using Dispase® as described above. PS and PO pellets were dissolved in $300\;\mu L$ Trizol reagent before processing by Direct-Zol RNA miniprep kit according to the manufacturer's instructions (Zymo Research; Cat. No. 11-331). cDNA synthesis was conducted by iScript cDNA synthesis kit (Bio-Rad, Cat. No. 1708891). Quantitative real-time PCR was conducted using SYBR green master mix reagent (Bio-Rad; Cat. No. 1725271) with CFX96 Real-Time system (Bio-Rad). Primer sequences are provided in Table S1. Data were analyzed with $- \Delta\Delta\text{Ct}$ method and normalized to the housekeeping gene RPL13.

Plasmids and Lentiviral Delivery {#s2.9}
--------------------------------

For knockdown, shRNA for the gene of interest was selected from Genetic Perturbation Platform (GPP) at Broad Institute (<https://portals.broadinstitute.org/gpp/public/>), where sequences are available through searching clone ID (TRCN \#). shRNA targeting p62 (TRCN0000007235), NRF2 (TRCN0000007558), ATG7 (TRCN0000007587), VMA5 (TRCN0000101541), and luciferase (TRCN0000072259) were cloned to pLKO.1-TRC (a gift from David Root, Addgene plasmid 10878) as described ([@c39]) or following cloning protocol on the GPP website (<https://portals.broadinstitute.org/gpp/public/resources/protocols>).

For overexpression, the protein coding sequences (CDS) of NRF2 and VMA5 were cloned from cDNA of human primary prostate epithelial cells by high-fidelity PCR using Phusion enzyme (New England Biolabs; Cat. No. M0530S). This was subcloned to a Tet-On overexpression lentiviral vector pLIX_402 (a gift from David Root, Addgene plasmid 41393) with a C-terminal HA tag. mCherry-EGFP-LC3B CDS were subcloned from pBabe-puro mCherry-EGFP-LC3B (a gift from Jayanta Debnath, Addgene plasmid 22418) to pLVX-puro (Clontech; Cat. No. 632164). Cloning was conducted with a Gibson Assembly Cloning Kit (New England Biolabs; Cat. No. E5510S). Lentiviral packaging and infection were conducted as described ([@c39]). Briefly, lentivirus was produced with a second packaging system with pMD2.G and psPAX2 plasmids (a gift from Didier Trono; Addgene plasmid 12259 and 12260) using HEK-293FT cells (ThermoFisher Scientific; Cat. No. R70007). Lentivirus-containing medium was collected 48 h post-transfection and stored at $–80ºC$. For infection using 6-well plates, $1\;{mL}$ prewarmed lentivirus-containing medium was added to cells at 70%--80% confluence in the presence of $8\;\mu g/{mL}$ polybrene, incubated at 37°C overnight and changed to $2\;{mL}$ fresh culture medium. Infected cells were selected with puromycin ($1\;\mu g/{mL}$) 24 h after infection for 1 wk, and then used for experiments.

Intracellular Reactive Oxygen Species (ROS) Assay {#s2.10}
-------------------------------------------------

To assess intracellular ROS, day-7 PS were collected from embedded culture by Dispase® digestion, dispersed to single cells by trypsin digestion for 5 min at 37°C and attached to chamber slides by overnight culture in Prostalife™ culture medium. Cells were incubated with $5\;\mu M$ 2′,7′-dichlorofluorescin diacetate (Setareh Biotech; Cat. No. 7543) for 10 min at 37°C before washing, fixing, and assessing with a fluorescent microscope.

Soft-Agar Colony Formation Assay {#s2.11}
--------------------------------

RWPE1 cells (10,000 cells/well) were mixed with 0.4% agarose in growth medium and plated on top of a solidified layer of 0.8% agarose in 6-well plates. After 3 wk, colonies were dyed with crystal violet ($1\;{mL}$ PBS containing 4% formaldehyde and 0.005% crystal violet per well), imaged with a dissecting microscope or EVOS FL Auto2 Cell Imaging System (Invitrogen), and quantified with ImageJ (<https://imagej.nih.gov/ij/>).

NRF2 Luciferase Reporter Assay {#s2.12}
------------------------------

To long-term monitor real-time NRF2 pathway activation in spheres, we created a lentiviral reporter with *Gaussia* luciferase (GLuc) expression under an artificial promoter containing NRF2 binding motifs. The lentiviral reporter was based on FUGW plasmid backbone ([@c33]), which was a gift from David Baltimore (Addgene plasmid 14883). First, we inserted a DNA fragment at BamHI restriction enzyme site, a fragment containing hPGK promoter, puromycin resistant gene, and T2A peptide from pLIX402 plasmid (a gift from David Root, Addgene plasmid 41393), which enabled a puromycin screening for lentivirus infected cells. Next, we replaced original hUBC promoter with a DNA fragment of NRF2 reporter using PcaI and BamH1 restriction enzyme sites. The NRF2 reporter fragment was synthesized by Integrated DNA Technologies (IDT) (gBlock gene fragments), which consisted of 3 NRF2 binding motifs (*[TGACTCAGCA]{.ul}*C*[TGACTCAGCA]{.ul}*G*[TGACTCAGCA]{.ul}*) followed by a mini-TK promoter and the coding sequence of a modified GLuc enzyme. The humanized coding sequence of wild-type Gluce was acquired from pGLuc-Basic 2 plasmid (New England Biolabs; Cat. No. N0802). The modified GLuc contains M43I and M110I mutations to yield an enzyme with glow-like properties ([@c73]) and thus more suitable for future high-throughput screening. In addition, we attached a synthetic fragment to GLuc that encoded the proteolytic "PEST" signal from mouse ornithine decarboxylase ([@c16]) to reduce the half-life of the GLuc protein dramatically, thus the NRF2 activation was monitored in real time. The NRF2 activation was quantified by measuring the activity of secreted GLuc. Cell culture medium containing GLuc was collected at appropriate time points, and $30\;\mu L$ was mixed with $30\;\mu L$ assay buffer containing GLuc substrate ($20\text{ mM}$ coelenterazine in PBS). Within 30 min, the bioluminescent signal (maximal emission at $470\text{ nm}$) produced by GLuc from the oxidation of coelenterazine was detected using a Glomax Multi Plus detection system (Promega; Cat. No. E7081) with Luminescence Module (Promega; Cat. No. E8041).

LysoHunt Assay {#s2.13}
--------------

All treatments were performed at 37°C. Live cells were incubated with culture medium containing $0.5\;\mu M$ LysoHunt for 60 min and imaged ($\text{excitation}/\text{emission} = 577/590\;\text{nm}$) by fluorescent microscopy (Zeiss Axioskop). Images were quantified with ImageJ (<https://imagej.nih.gov/ij/>).

Recombinants of Chimeric Prostatelike Structures {#s2.14}
------------------------------------------------

*In vivo* tissue recombinant experiments used PrSPCs mixed with rat embryonic urogenital sinus mesenchyme (UGM) and grafted under the renal capsule of 6-wk-old male nude mice as described previously ([@c21], [@c19]). All animals were handled according to Principles for Care and Use of Animal Research and Studies approved by the Institutional Animal Care Committee. Timed pregnant female Sprague-Dawley rats were purchased from Harlan, as well as male nude mice. Animals were housed in polysulfone solid-bottom cages at 21°C with 14-h light/10-h dark cycle with water supplied from glass bottles and standard Purina® rodent chow *ad libitum*.

Rat embryonic day-17 fetuses were collected by Caesarian section under ketamine/xylazine (5:2, University of Illinois at Chicago pharmacy) anesthesia; the urogenital sinus (UGS) was removed and digested; and the UGM was separated from the urogenital epithelium (UGE). After microscopically confirming absence of UGE, the UGM was used for tissue recombination. For each graft, $\sim 3000$ PrSPCs from dispersed PS were mixed with UGM from 1 embryo and resuspended in $10\;\mu L$ Matrigel®. Recombinants were incubated overnight on 1% agar in DMEM in 5% CO2 at 37°C prior to grafting under the renal capsule of 7- to 8-wk-old male nude mice as previously described ([@c23]) with each kidney receiving 1 graft. Grafts with UGM or UGE alone were used for quality controls. Recipient mice were supplemented with testosterone-containing containing SILASTIC (Dow Corning Corp.) capsules ($0.5\;{cm}$) that produced serum testosterone levels of $12.7\text{ ng}/\text{mL}$ at 1 month.

Due to the differing iAs pharmacokinetics in rodents and humans, higher iAs must be provided orally to mice to reach similar blood levels in humans exposed to lower doses ([@c62]; [@c68]). The doses aim to mimic typical human exposure levels in geographic hotspots and in occupational settings. For iAs exposure, mice bearing renal grafts were exposed to $5\text{ ppm}$ iAs in the drinking water, which mimics iAs in geographical hotspots ([@c62]), and grafts were harvested after 3 months for histological analysis. A total of 9 mice (18 grafts) were treated with $5\text{ ppm}$ ($65\;\mu M$) iAs in the drinking water, and 5 control mice (10 grafts) had no exposure in the water. Animals were anesthetized with isoflurane prior to tissue collections, and animals were euthanized by cervical dislocation.

Statistical Analysis {#s2.15}
--------------------

Data were analyzed using GraphPad Prism version 6.0 (GraphPad Software Inc.) and presented as $\text{mean} \pm \text{SEM}$. Statistically significant differences were assessed by Student's *t*-test or, with multiple groups, analysis of variance (ANOVA), followed by Tukey-Kramer or Student-Newman-Keuls post hoc tests. $p < 0.05$ was considered significant.

Results {#s4}
=======

Self-Renewal and Differentiation of PrSPCs Treated with or without 0.5 to $50\;\mu M$ Arsenic {#s4.1}
---------------------------------------------------------------------------------------------

To determine the effects of iAs on primary PrSPCs grown from disease-free human primary PrEC cultures, we studied two unique properties of stem-progenitor cells: self-renewal and differentiation. The sphere formation assay enriches stem-progenitor cells based on their unique capability to survive and expand in 3D serum-free culture, whereas differentiated primary cells undergo apoptosis or senescence. The number and size of prostate spheres (PS) represents stem cell self-renewal and progenitor cell proliferation capacity, respectively ([@c21], [@c20]; [@c44]). Low-dose iAs ($1\;\mu M$) increased, whereas higher-dose iAs ($5–50\;\mu M$) decreased total PS numbers ([Figure 1A](#f1){ref-type="fig"}; PS $> 40\;\mu M$). Size analysis revealed that $1\;\mu M$ iAs markedly increased the formation of medium-sized ($40–80\;\mu M$) PS, whereas iAs at higher doses suppressed formation of medium and large ($> 80\;\mu M$) PS ([Figure 1B](#f1){ref-type="fig"}). A Hoechst exclusion assay was next used to quantitate the stem-like cell population in 2D primary PrEC cultures upon iAs exposure. Consistent with PS formation assay results, $1\;\mu M$ iAs increased and $5\;\mu M$ iAs decreased the percentage of stem-like cells ([Figure 1C](#f1){ref-type="fig"}). Of note, iAs significantly suppressed proliferation of 2D-cultured PrECs at all iAs doses including $0.1\;\mu M$, suggesting that differentiated primary cells are highly sensitive to iAs exposure (Figure S1A). Further, the higher-dose iAs ($5\;\mu M$) induced early apoptosis and G1 cell cycle arrest, whereas lower-dose iAs ($1\;\mu M$) had no significant effect on cell cycle progression (Figure S1B, S1C). Thus, $1\;\mu M$ was used for further experiments, because this dose was nontoxic to PrECs and mimics environmentally relevant iAs exposures.

![Effects of arsenic on self-renewal and differentiation of prostate stem-progenitor cells. (A,B) Prostate spheres (PS) derived from primary human prostate epithelial cells (PrEC) were cultured with inorganic arsenic (iAs) at indicated doses for 7 d (PrEC-D7PS) (A) and quantified according to size (B). $\text{Scale\ bar} = 200\;\mu m$. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 3–4$); \*$p < 0.05$ vs. vehicle. (C) Percentage of stem-like cell side population in 2-dimensional cultured PrEC (PrEC-2D) using a Hoechst exclusion side-population assay. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. vehicle. (D) Immunostaining of KRT14 and KRT8/18 in recombinant human rat prostate gland structures in nude mice renal grafts exposed to vehicle or $5\text{ ppm}$ iAs in drinking water for 3 months. Red: KRT14, basal epithelial cells. Green: KRT8/18, luminal epithelial cells. $\text{Scale\ bar} = 20\;\mu m$ (left: low power; right: high power). (E) mRNA level of prostate epithelial differentiation genes in 2-wk cultured prostate organoid (D14PO) and prostate spheres (D14PS) derived from PrEC. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. D14PS. (F) mRNA levels of prostate epithelial differentiation genes in D14PO treated $\pm 1\;\mu M$ arsenic. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle. (G) KRT18 protein level of D20PO treated $- / + 1\;\mu M$ arsenic. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. vehicle.](ehp6471_f1){#f1}

Lineage commitment and cell differentiation capability are essential features of stem-progenitor cells that permit tissue homeostasis. In the human prostate, PrSPCs give rise to basal cells, luminal PrECs, and rare neuroendocrine cells ([@c58]). Because iAs alters differentiation in a variety of stem-progenitor cells ([@c3]; [@c37]; [@c50]; [@c77]), we tested whether iAs influences this process in PrSPCs. Primary PrSPCs cultured for 7 d from disease-free PrECs were isolated and mixed with embryonic rat urogenital sinus mesenchyme (UGM) and grafted under renal capsules of nude mice. The hosts were exposed to 0 or $5\text{ ppm}$ ($65\;\mu M$) iAs in drinking water for 3 months. The PrSPCs formed normal prostate gland structures with basal ($\text{KRT}14 +$) and luminal ($\text{KRT}8/18 +$) epithelial cells in control hosts ([Figure 1D](#f1){ref-type="fig"}). In contrast, expression of KRT14 and KRT8/18 in the graft epithelial cells was markedly lower in iAs-treated mice vs. controls, indicating suppressed prostate epithelial differentiation. As an alternative approach, 3D prostate organoid (PO) culture, which drives epithelial differentiation, was used to assess iAs effects on this process. Compared with PS cultures, PO cultured from primary PrECs expressed prostate epithelial differentiation genes (*CEACAM6*, *LCN2*, and *S100P*) ([@c46]) as well as marker genes for basal (*KRT5*) and luminal (*KRT8*) cells ([Figure 1E](#f1){ref-type="fig"}). Consistent with *in vivo* data, iAs significantly inhibited expression of these differentiation marker genes ([Figure 1F](#f1){ref-type="fig"}). KRT8 suppression was further confirmed at the protein level ([Figure 1G](#f1){ref-type="fig"}).

Microarray Analysis and Subsequent Evaluation of the NRF2 Pathway in PrSPCs Treated with or without $1\;\mu M$ Arsenic {#s4.2}
----------------------------------------------------------------------------------------------------------------------

To investigate the underlying mechanisms of PrSPC perturbation, we analyzed the transcriptomes of $1\;\mu M$ iAs-treated PS and PO using microarrays. Although nonsupervised clustering revealed that the majority of differences were between PO and PS ([Figure 2A](#f2){ref-type="fig"}), iAs-regulated genes were consistently observed in both PS and PO groups. Because the focus of this study was stem and progenitor cells, we concentrated on iAs-regulated genes in the PS groups. At the mechanistic level, revealed by Wikipathway analysis ([@c69]), oxidative stress and KEAP1-NRF2, among others, were top enriched pathways in iAs-treated PS ([Figure 2B](#f2){ref-type="fig"}) as was prostate cancer, supporting PrSPCs as compelling oncogenic targets of iAs. Using gene sets of oncogenic signatures, gene set enrichment analysis (GSEA) revealed that iAs up-regulated well-known oncogenic molecular pathways in PrSPCs, including KRAS, PTEN-deficiency, P53-deficiency, and ERK pathways ([Figure 2C](#f2){ref-type="fig"}).

![Effects of arsenic on the NRF2 pathway in prostate stem-progenitor cells. (A) Heatmap showing the top 1,000 differentially expressed genes across four groups: prostate spheres $- / +$ arsenic (PS_Veh, PS_iAs), prostate organoids $- / +$ arsenic (PO-Veh, PO-iAs). Prostate spheres and organoids were derived from primary human prostate epithelial cells (PrEC), and cultured $- / + 1\;\mu M$ arsenic for 2 wk. (B) Top 10 iAs up-regulated pathways in prostate spheres, iAs up-regulated genes ($\text{fold\ change} > 2$, adjusted $p < 0.05$) were sorted for pathway analysis with Wikipathway. (C) Enriched oncogenic pathways in PS_iAs group vs. PS_Veh group. Raw microarray data were subject to GSEA analysis using gene sets of oncogenic signatures. (D) GSEA data showing NRF2 pathway enrichment between PS-iAs and PS-Veh groups (top) and most regulated genes of NRF2 pathway (bottom). (E) mRNA level of NRF2 pathway genes in PS_Veh and PS_iAs group. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle. (F) Representative NRF2 immunostaining showing nuclear translocation in PS upon $1\;\mu M$ iAs treatment for 7 d (PrEC-D7PS). $\text{Scale\ bar} = 20\;\mu m$. (G) Immunoblot of HMOX1 in PrEC-D7PS $- / + 1\;\mu M$ iAs treatment. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. vehicle. (H) Representative HMOX1 immunostaining in day-7 spheres derived from primary human prostate epithelial cells (PrEC-D7PS) with indicated treatment, $n > 4$. iAs, $1\;\mu M$ arsenic; shLuc, negative control shRNA targeting luciferase gene; shNRF2, shRNA targeting NRF2 gene; Veh, vehicle control. $\text{Scale\ bar} = 20\;\mu m$. (I) NRF2-luciferase reporter assay showing luciferase activity in PrEC-D7PS $- / + 1\;\mu M$ iAs. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle.](ehp6471_f2){#f2}

As a master antioxidative transcription factor, NRF2 is also involved in tumorigenesis and stem cell function regulation, but its role in PrSPCs remains unclear. To examine this further, microarray results were validated with qPCR, revealing that iAs significantly increased expression of NRF2 marker genes *NQO1*, *HMOX1*, *GPX2*, and *GLCM* ([Figure 2D,E](#f2){ref-type="fig"}). Although *NRF2* mRNA was not affected by iAs, cytoplasmic-to-nuclear translocation of NRF2 indicated that iAs activated NRF2 at the post-translational level ([Figure 2F](#f2){ref-type="fig"}). Induction of HMOX1 (the top up-regulated NRF2 pathway gene) and NQO1 was further confirmed by immunoblotting ([Figure 2G](#f2){ref-type="fig"}). *NRF2* knockdown by shRNA (shNRF2) (Figure S2) attenuated the elevated HMOX1 immunofluorescence induced by iAs ([Figure 2H](#f2){ref-type="fig"}), indicating that *HMOX1* was downstream of NRF2 activation. A luciferase reporter with an artificial NRF2 binding motif that was introduced into PS by lentivirus revealed that iAs exposure significantly increased luciferase activity, confirming direct NRF2 activation by iAs ([Figure 2I](#f2){ref-type="fig"}).

Effects of NRF2 Loss and Gain of Function on PrSPC Cells Treated with Arsenic {#s4.3}
-----------------------------------------------------------------------------

Because studies of hematopoietic stem cells demonstrate that their quiescence and capacity for bone marrow reconstitution are compromised by NRF2 activation ([@c66]), we tested whether NRF2 may similarly regulate PrSPC homeostasis. GSEA revealed enrichment of the NRF2 pathway genes in PS relative to differentiated PO culture, whereas iAs mitigated this difference ([Figure 3A](#f3){ref-type="fig"}). PrSPC responses to NRF2 loss- and gain-of-function were next examined. shNRF2 markedly induced expression of differentiation genes in 2D-cultured PrECs ([Figure 3B](#f3){ref-type="fig"}) and reduced PS formation upon transfer to 3D culture ([Figure 3C](#f3){ref-type="fig"}), suggesting a critical role for NRF2 in maintaining stemness. In contrast, the NRF2 inducer Oltipraz significantly increased PS formation and size ([Figure 3D](#f3){ref-type="fig"}). Further, overexpression of NRF2 in PS using a Tet-On expression system showed that forced NRF2 expression similarly significantly increased NRF2 target gene expression ([Figure 3E](#f3){ref-type="fig"}) as well as PS number and size ([Figure 3F](#f3){ref-type="fig"}), suggesting that NRF2 enhances self-renewal of PrSPCs.

![The role of NRF2 plays in iAs-induced transformation. (A) GSEA data of NRF2 pathway genes comparing prostate organoids (PO) and spheres (PS) derived from primary human prostate epithelial cells (PrEC) and treated with vehicle (PO-V vs. PS-V) or $1\;\mu M$ arsenic (PO-As vs. PS-As). (B) Expression of prostate epithelial differentiation genes in 2-dimensional culture PrEC (PrEC-2D) with NRF2 knockdown (shNRF2). Data shown are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. shRNA control (shLuc). (C) Sphere formation capability of PrEC with NRF2-knockdown, D7PS: day-7 spheres. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle. (D) Quantification of sphere formation capability of PrEC treated with NRF2-inducer Oltipraz ($10\;\mu M$) for 7 d. D7PS: day-7 prostate spheres. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle. (E) mRNA level of NRF2 gene and NRF2 pathway marker genes. Tet-On NRF2 expression was induced in PrEC spheres by lentivirus. Spheres were $\text{culture} - / + \text{ doxycycline}$ (Dox, $0.5\text{ ug}/\text{mL}$) for 7 d (Tet-ON-NRF2 PrEC-D7PS) to induce NRF2 overexpression. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle. (F) Quantification of sphere formation capability of PrEC with Tet-On overexpression of NRF2. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle. (G) Soft-agar colony formation assay of RWPE1 with indicated treatment. Note: iAs, inorganic arsenic; shLuc, RWPE1 with shRNA targeting luciferase gene, negative control; shNRF2, RWPE1 with NRF2 knockdown. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. shRNA control (shLuc).](ehp6471_f3){#f3}

NRF2 plays both pro-oncogenic and antioncogenic roles in tumor progression ([@c26]; [@c56]). To determine whether it plays a role in iAs-induced transformation, the effects of *NRF2* knockdown on iAs-induced tumorigenesis were investigated using a soft-agar colony formation assay. Because this assay was not possible using primary cells, we used RWPE1 cells that are known to be transformed by extended iAs exposure ([@c5]; [@c64]). As expected, 3-wk exposure to $1\;\mu M$ or $5\;\mu M$ iAs significantly increased soft-agar colony formation in a dose-dependent manner in comparison with vehicle controls ([Figure 3G](#f3){ref-type="fig"}). Of significance, shNRF2 abrogated this iAs-induced colony formation activity.

Evaluation of ROS and p62 Regulation of NRF2 Activity in Arsenic Exposed PrSPCs {#s4.4}
-------------------------------------------------------------------------------

NRF2 activity is primarily regulated in a negative fashion by KEAP1, which targets NRF2 for proteasome degradation. During canonical NRF2 activation, electrophilic or oxidative stress modifies cysteine residues of KEAP1, which disrupts KEAP1-mediated degradation and stabilizes NRF2 ([@c26]). Although high-dose iAs has been shown to induce production of reactive oxygen species (ROS) ([@c8]), we did not observe increased ROS production in PrSPCs after treatment with low-dose $1\;\mu M$ iAs ([Fig. 4A](#f4){ref-type="fig"}). In fact, low-dose iAs attenuated hydroperoxide-induced ROS production in these cells. Further, $1\;\mu M$ iAs-induced HMOX1 expression was not suppressed by the ROS scavenger N-acetyl cysteine ([Figure 4B](#f4){ref-type="fig"}), suggesting that low-dose iAs-induced NRF2 activation is not mediated through ROS in PrSPCs.

![Mechanism of arsenic activation of the NRF2 pathway and autophagy dependence. (A) DCFDA assay showing intracellular levels of reactive oxygen species (ROS) in day-7 prostate spheres derived from primary human prostate epithelial cells (PrEC-D7PS) upon indicated treatment. iAs, treated with $1\;\mu M$ inorganic arsenic (iAs) for 7 d; $H_{2}O_{2}$, treated with $100\;\mu M$ hydroperoxide for 30 min; Veh, vehicle. $\text{Scale\ bar} = 20\;\mu m$. (B) Immunoblotting of p62 and HMOX1 protein from day-7 spheres of primary human prostate epithelial cells (PrEC-D7PS) with indicated treatment: iAs treated for 0, 4, 16 h (16h) and 7 d (7D) without (Veh) or with $1\text{ mM}$ N-acetyl cysteine (NAC) 30 min prior to iAs exposure. (C) Immunoblot of p-p62 (S349), p62, NQO1 and HMOX1 protein from day-7 spheres of RWPE1 cells (RWPE1-D7PS) with indicated treatment. iAs, inorganic arsenic; shLuc, negative control shRNA targeting luciferase gene; shP62, shRNA targeting p62 gene. Quantification data shown are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. shRNA control (shLuc). (D) Soft-agar colony formation capability of RWPE1 with indicated treatment: $1\;\mu M$ iAs; shLuc, negative shRNA control targeting luciferase gene; shP62, shRNA targeting p62 gene. Quantification data are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. shRNA control (shLuc). (E) Immunoblot of phosphorylation at p62-serine349 from day-7 spheres of primary human prostate epithelial cells (PrEC-D7PS) treated with $1\;\mu M$ iAs for 7 d. Quantification data are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. vehicle control. (F) Immunoblot of indicated proteins from day-7 spheres derived from primary human prostate epithelial cells (PrEC-D7PS) treated with $1\;\mu M$ iAs for 7 d with indicated treatment. shATG7, shRNA targeting ATG7 gene; shLuc, negative control shRNA targeting luciferase gene. Quantification data are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. shRNA control (shLuc).](ehp6471_f4){#f4}

Recently, noncanonical p62-dependent NRF2 activation was identified in which p62 competitively binds KEAP1, thus preventing NRF2 degradation ([@c26]; [@c29]). Given that iAs induces noncanonical NRF2 activation in a variety of 2D-cultured cells ([@c14]), we examined whether iAs activated NRF2 in PrSPCs through the p62-KEAP1-NRF2 pathway. Indeed, p62 levels increased in PS within 16 h of $1\;\mu M$ iAs exposure, concomitant with HMOX1 induction ([Figure 4B](#f4){ref-type="fig"}). In PrSPCs derived from RWPE1 cells, iAs increased p-p62 (S349), NQO1, and HMOX1 levels, whereas knockdown of p62 attenuated these responses ([Figure 4C](#f4){ref-type="fig"}) and decreased their soft-agar colony formation capability ([Figure 4D](#f4){ref-type="fig"}). Phosphorylation of p62-S349 (S351 for mouse) increases its KEAP1-binding capability ([@c25]) and iAs increased p62-S349 phosphorylation in PrSPCs from normal prostate epithelial cells as well ([Figure 4C,E](#f4){ref-type="fig"}), supporting iAs activation of p62-KEAP1-NRF2. Because p62-S349 modification depends on autophagy initiation, the role of autophagy in iAs-induced NRF2 activation was examined. Significantly, blockade of autophagy initiation by *ATG7* knockdown suppressed iAs-induced HMOX1 ([Fig. 4F](#f4){ref-type="fig"}), suggesting that iAs actions may involve autophagy in PrSPCs.

Autophagic Flux Activity in PrSPCs Exposed to $1\;\mu M$ Arsenic {#s4.5}
----------------------------------------------------------------

Previous studies have reported that iAs can either activate or inhibit autophagy, depending on the context of dosage and cell type ([@c45]). To examine a potential role of autophagy in iAs-induced NRF2 activation, we examined the effects of iAs on autophagy of PrSPCs in greater detail.

Microtubule-associated protein 1A/1B-light chain 3 (LC3) is a marker of autophagy and is ubiquitously distributed in cells. After autophagy initiation, the cytosolic form of LC3 (LC3-I) is converted to LC3-II by lipidation and recruited to autophagosome membranes. SQSTM/p62 (p62) is an autophagy protein that delivers cargo to the autophagosome for degradation and is also degraded with cargo in the lysosome. Thus, autophagic flux, a measure of autophagic degradation activity, can be assessed by the status of LC3 and p62. Exposure to $1\;\mu M$ iAs induced autophagosome accumulation in PrSPCs ([Figure 5A](#f5){ref-type="fig"}). Further, iAs significantly increased both LC3B-II and p62 protein levels ([Figure 5B](#f5){ref-type="fig"}), whereas mRNA levels were not significantly affected ([Figure 5C](#f5){ref-type="fig"}), suggesting that autophagosome accumulation may be a result of impaired degradation. Indeed, cotreatment with the lysosome inhibitor chloroquine did not significantly increase LC3B-II accumulation after iAs treatment ([Figure 5D](#f5){ref-type="fig"}), which suggests autophagic flux blockade.

![Arsenic effects on autophagic flux in prostate stem-progenitor cells. (A) Spheres of primary human prostate epithelial cells (PrEC-D7PS) were treated with $1\;\mu M$ inorganic arsenic ($1\;\mu M$ iAs) for 7 d, and single cells of spheres were attached to chamber slides overnight for immunostaining. Autophagosomes were visualized with LC3B staining as green puncta. Puncta in single cells were counted and quantified data shown are $\text{mean} \pm \text{SEM}$ ($n = 12$ cells from wells of same slide); \*$p < 0.05$ vs. vehicle control. $\text{Scale\ bar} = 20\;\mu m$. (B) Immunoblots of p62 and LC3B protein from PrEC-D7PS treated with iAs. Quantified data are $\text{mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle control. (C) mRNA level of p62 and LC3B from PrEC-PS treated with arsenic for 48 h (iAs_48h) or 7 d (iAs_7d). Data are $\text{mean} \pm \text{SEM}$ ($n = 3$); no significant difference vs. vehicle. (D) Immunoblots of LC3B from PrEC-D7PS with indicated treatment. Spheres were cultured with iAs, and chloroquine (CQ, $25\;\mu M$) was added 4 h before sample collection. Arrowheads indicate lipidified LC3B-II blots at two exposure lengths. The top blot of a long exposure time shows the unmodified LC3B-I, which migrates more slowly than the lipidified LC3B-II. The bottom blot shows a shorter exposure time where relative levels were quantified. Quantification data are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. vehicle control; NS, $p > 0.05$ between two groups. (E) Schematic of the autophagic flux reporter EGFP-mCherry-LC3. (F) Confocal images showing GFP and mCherry in autophagosomes/autolysosomes in PrEC-D7PS overexpressing flux reporter. Arrowheads indicate GFP-mCherry-LC3 positive puncta of autophagosomes/autolysosomes. (G) Flow cytometry data quantification of GFP and mCherry intensity of PrEC-D7PS cells, over-expressing flux reporter, after indicated treatment. BafA1, $100\;\mu M$ treatment for 4 hrs; HBSS, cells treated with Hank's Balanced Salt Solution (HBSS) overnight; iAs, $1\;\mu M$ treated for 7 d; Veh, vehicle. Number indicates the ratio of mCherry/GFP for the inset.](ehp6471_f5){#f5}

To directly assess iAs-induced blockade, an autophagic flux reporter of tandem fluorescent-tagged LC3 (mCherry-GFP-LC3) was used. By integrating to the autophagosome membrane, mCherry-GFP-LC3 fusion protein is delivered to the lysosome, where acidic conditions ($\text{pH} < 5$) quench GFP, whereas the mCherry signal remains ([Figure 5E](#f5){ref-type="fig"}). The ratio of mCherry and GFP fluorescence (mCherry/GFP) reflects autophagic flux. Foci with high mCherry and low GFP signal were observed in vehicle-treated PrSPCs ([Figure 5F](#f5){ref-type="fig"}). In contrast, iAs induced more foci with colocalization of mCherry and GFP, indicating flux blockade. Quantification by flow cytometry ([Figure 5G](#f5){ref-type="fig"}) showed that iAs exposure decreased the mCherry/GFP ratio by $\sim 50\%$; Hank's Balanced Salt Solution (HBSS), an autophagy inducer, increased the mCherry/GFP ratio; whereas BafA1, a lysosome inhibitor, decreased the mCherry/GFP ratio. Together the findings show that iAs induces autophagic flux blockade, resulting in p62 accumulation in PrSPCs.

Effects of Arsenic on Lysosome Acidification V-ATPase Expression {#s4.6}
----------------------------------------------------------------

Autophagy uses a lysosomal degradation pathway, and inhibitors of lysosome acidification have been shown to block autophagic flux. As such, the effects of iAs on lysosome acidification were next interrogated. Use of LysoHunt Red, a fluorescent dye that localizes to acidic organelles of living cells, revealed that iAs suppressed organelle acidification of PrSPCs ([Figure 6A](#f6){ref-type="fig"}). Vacuolar ATPase (V-ATPase) plays a central role in organelle acidification ([@c35]), and the specific V-ATPase inhibitor BafA1 similarly inhibited organelle acidification in PrSPCs ([Figure 6A](#f6){ref-type="fig"}). We thus evaluated whether iAs inhibited lysosome acidification by suppressing V-ATPase function. V-ATPase is a multisubunit enzyme that is highly conserved among eukaryotes, consisting of a cytosolic ATP-hydrolytic V1 domain and a transmembrane proton-translocation V0 domain ([@c35]). Transcriptome analysis revealed that iAs markedly suppressed ATP6V1C2 (*VMA5*) in PrSPCs, which was further confirmed by qPCR ([Figure 6B](#f6){ref-type="fig"}) and immunoblotting ([Figure 6C](#f6){ref-type="fig"}). This was not a function of reduced lysosome levels because LAMP1, a lysosome marker, was not altered by iAs treatment (Figure S3A).

![Arsenic effects on lysosome acidification and expression of V-ATPase subunit VMA5. (A) LysoHunt staining showing acidification of organelles from day-4 spheres of primary human prostate epithelial cells (PrEC-D4PS) cultured on low-attached plate with indicated treatment. Higher intensity of red signal from LysoHunt indicates higher acidification. BafA1, bafilomycin A1, V-ATPase inhibitor, $100\text{ nM}$ treatment for 2 h; iAs, $1\;\mu M$ iAs treatment for 4 d; Veh, vehicle. Quantification data are $\text{mean} \pm \text{SEM}$ ($n = 10–13$ spheres from wells of same low-attach plate); \*$p < 0.05$ vs. vehicle. (B) mRNA level of VMA5 gene in D7PS of RWPE1 and PrEC treated with $1\;\mu M$ iAs for 7 d. $\text{Mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. vehicle. (C) Immunoblot of VMA5 protein in PrEC-D7PS treated with $1\;\mu M$ iAs for 7 d. $\text{Mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. vehicle. (D) mRNA level of VMA5 in PrEC with shRNA targeting VMA5 (shVMA5). $\text{Mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. shRNA control (shLuc). (E) LysoHunt staining showing acidification of organelles from day-4 spheres of primary human prostate epithelial cells (PrEC-D4PS) with VMA5 gene knockdown (shVMA5). Quantitative data are $\text{mean} \pm \text{SEM}$ ($n = 10–15$); \*$p < 0.05$ vs. shRNA control (shLuc). (F) Immunoblotting of p62 and LC3B from PrEC-D7PS with VMA5 gene knockdown (shVMA5). $\text{Mean} \pm \text{SEM}$ ($n = 4$); \*$p < 0.05$ vs. shRNA control (shLuc). (G) Immunoblot of indicated protein in PrEC-D7PS with Tet-On VMA5 overexpression treated with $1\;\mu M$ iAs for 7 d. Doxycycline (Dox, $0.5\text{ ug}/\text{mL}$) was added to induce VMA5 overexpression for 7 d. Quantification data are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. vehicle control.](ehp6471_f6){#f6}

*VMA5* encodes the subunit C of the V-ATPase V1 domain, and studies with yeast and fruit flies indicate that VAM5 is essential for V-ATPase assembly ([@c35]). To determine whether VMA5 plays a functional role in iAs-induced autophagic flux blockade, we knocked-down *VMA5* in PrECs ([Figure 6D](#f6){ref-type="fig"}) and generated 3D PS cultures. *VMA5* knockdown significantly suppressed acidification of intracellular organelles ([Figure 6E](#f6){ref-type="fig"}). An important finding is that *VMA5* knockdown induced autophagic flux blockade, as shown by significant accumulation of LC3B-II and p62 ([Figure 6F](#f6){ref-type="fig"}). Although VMA5 loss did not elevate HMOX1 expression (Figure S3B), VMA5 overexpression in PS using a Tet-On system significantly attenuated iAs-induced HMOX1 and p62 accumulation ([Figure 6G](#f6){ref-type="fig"}) but had no effect on basal HMOX1 expression in vehicle control (Figure S3C).

Evaluation of NRF2 Pathway Activation in Separate Prostate Stem, Progenitor, and Differentiated Cells {#s4.7}
-----------------------------------------------------------------------------------------------------

Upon asymmetric cell division, prostate stem cells give rise to daughter progenitor cells that proliferate and give rise to differentiated cell types. To better understand the primary targets of iAs exposures, we next assessed NRF2 activation as a function of treatment with $1\;\mu M$ iAs in these three cell populations. Compared with the 3D PS cells, the parenteral differentiated 2D primary PrECs had higher p62 and lower LC3B-II/LC3-I ratio levels, indicating lower basal autophagy activity ([Figure 7A](#f7){ref-type="fig"}). Despite subtle HMOX1 induction, iAs treatment had no obvious effect on p62 and LC3B-II levels in 2D PrECs ([Figure 7A](#f7){ref-type="fig"}) indicating that these pathways are not arsenic targets in differentiated prostate epithelial cells.

![Assessment of arsenic effects on the NRF2 pathway in progenitor cells and their progeny. (A) Representative immunoblotting ($n > 3$) of indicated protein in primary human prostate epithelial cells (PrEC) under indicated culture condition with inorganic arsenic (iAs). 2D, 2-dimensional cultured PrEC represent differentiated prostate epithelial cells; 3D, 3-dimensional cultured PrEC represent prostate stem-progenitor cells. (B--D) Representative immunostaining of BrdU and indicated protein in day-7 sphere derived from PrEC (PrEC-D7PS) treated with $1\;\mu M$ iAs for 7 d. BrdU-positive cells represent quiescent stem cells. BrdU-negative cells represent transient amplifying progenitor cells. Quantification data of iAs-induced HMOX1(b)/p62(c)/VMA5(d) expression in stem cells ($\text{BrdU-positive}$) and progenitor cells ($\text{BrdU-negative}$). Data shown are $\text{mean} \pm \text{SEM}$ ($n = 7–10$ paired cells from same staining); \*$p < 0.05$ between two groups.](ehp6471_f7){#f7}

Using a long-term bromodeoxyuridine (BrdU)-retaining assay in PS ([@c19], [@c18]), we next studied NRF2 activation in the separate stem and progenitor cell populations. In the prostate spheres, relative quiescent stem cells retain 2D-labeled BrdU, whereas the rapidly proliferating progenitor cells dilute BrdU-label through cell division ([@c19]), permitting identification of the two cell populations. Surprisingly, iAs induced much higher HMOX1, a marker of NRF2 activation, in BrdU-negative progenitor cells than in BrdU-positive stem cells ([Fig. 7B](#f7){ref-type="fig"}). Because prostate stem cells have higher autophagic flux in comparison with progenitor cells ([@c19]), it is possible that the stem cells have a higher capacity to overcome iAs-induced flux blockade. Indeed, p62 protein levels were lower in stem cells in comparison with daughter progenitor cells under basal conditions as well as upon iAs-exposure ([Figure 7C](#f7){ref-type="fig"}). Because iAs blocked autophagic flux by VMA5 suppression, we next examined VMA5 expression in the PS stem and progenitor cell types. Markedly higher VMA5 expression was observed in the BrdU-retaining stem cells and remained high expression even upon iAs exposure ([Figure 7D](#f7){ref-type="fig"}). These results indicate that the progenitor cells may be the primary iAs targets in the prostate and further confirm the essential role of VMA5 in iAs-induced NRF2 action as well.

Ability of Arsenic Exposure to Induce Chronic NRF2 Activation and Prostate Cell Transformation {#s4.8}
----------------------------------------------------------------------------------------------

Transcriptomic analysis indicated that iAs activated the NRF2 pathway in day-14 PO cultures ([Figure 8A](#f8){ref-type="fig"}), which was confirmed by elevated protein levels of p62 and HMOX1 in iAs-exposed organoids ([Figure 8B](#f8){ref-type="fig"}). Because differentiated PrECs are largely resistant to iAs-induced NRF2 activation ([Figure 7A](#f7){ref-type="fig"}), we hypothesized that NRF2 activation in differentiating PO epithelial cells might be a result of iAs initially targeting the progenitor cell population that forms the organoids over a 14-d time span. To test whether iAs-induced effects on progenitor cells could be carried forward to their unexposed progeny, we examined the transformation status of unexposed daughter cells following iAs-pretreatment of progenitor cells. RWPE1 cells were transferred to spheroid culture w/wo $1\;\mu M$ iAs for 1 wk. The PS were collected, dispersed to single cells, and transferred to soft-agar culture for 3 wk in the absence of iAs to assess transformation. Compared with vehicle control cells, progeny cells of iAs-pretreated PS formed significantly more colonies ([Figure 8C](#f8){ref-type="fig"}), suggesting that iAs-induced transformation initiates in progenitor cells and is passed forward to daughter cells.

![Assessment of arsenic effects on the NRF2 pathway in the progeny of progenitor cells. (A) GSEA NRF2 pathway enrichment analysis of prostate organoid (PO) treated with $1\;\mu M$ iAs for 14 d. NES, normalized enrichment score. $\text{NES} = 2.12$ indicates that NRF2 pathway is enriched in PO_iAs groups. (B) Representative immunoblotting of HMOX1 and p62 in day-14 prostate organoid derived from PrEC (PrEC-D14PO) treated with $1\;\mu M$ iAs for 14 d. Quantification data shown are $\text{mean} \pm \text{SEM}$ ($n = 3$); \*$p < 0.05$ vs. vehicle. (C) Representative image of soft-agar transformation assay of prostate stem-progenitor cells pretreated with $1\;\mu M$ iAs for 7 d. Quantification data of soft-agar colony formation efficiency are $\text{mean} \pm \text{SEM}$ ($n = 6$); \*$p < 0.05$ between two groups. (D) Representative immunostaining ($n > 3$) of indicated protein in chimeric human prostate gland structure derived from human PrEC and rat UGM grafted under renal capsule exposed to $5\text{ ppm}$ iAs in drinking water for 3 months. $\text{Scale\ bar} = 100\;\mu m$. (E) Quantitative data of Ki67 positive cell percent in chimeric human prostate gland. Data shown are $\text{mean} \pm \text{SEM}$ ($n = 5$ chimeric gland); \*$p < 0.05$ between two groups.](ehp6471_f8){#f8}

Consistent with the *in vitro* studies, immunostaining of *in vivo* renal grafts of prostate cell-tissue recombinants revealed that 3 months of iAs exposure led to higher protein levels of p62, NRF2, and HMOX1 in the human-derived epithelial cells and p62 and HMOX1 in the rat-derived stromal cells compared with controls, suggesting chronic activation of the NRF2 pathway ([Figure 8D](#f8){ref-type="fig"}). Although no overt pathologic changes were observed in comparison with vehicle grafts, chronic iAs exposure decreased tumor suppressor PTEN levels, consistent with previous *in vitro* studies in PrECs ([@c63]) and increased the number of Ki67-positive proliferating epithelial cells ([Figure 8E](#f8){ref-type="fig"}), hallmarks of a precancerous state.

Discussion {#s5}
==========

Using normal human primary cells, we herein demonstrate that iAs, at doses relevant to human exposures, disturbs homeostasis of PrSPCs through constitutive NRF2 activation in prostate progenitor cells, leading to their accumulation due to enhanced proliferation and suppressed differentiation. Cancer may arise from maturation arrest during progression of stem cells to transient amplifying progenitor cells and on to differentiated cells ([@c12]). Perturbations of this formative process could have long-term effects that drive increased prostate cancer risk susceptibility. Indeed, continuous iAs exposures led to transformation of PrSPCs *in vitro*, which was mitigated by *NRF2* knockdown. Similarly, *in vivo* iAs exposure activated NRF2 in prostate chimeric grafts, which initiated a pre-malignant molecular phenotype in the human prostate epithelium. Mechanistically, iAs activated NRF2 through a noncanonical p62-dependent pathway in which p62 accumulated from iAs-induced autophagic flux blockade, a result of suppressed lysosomal protein degradation due to attenuated lysosome acidification. Specifically, we found that iAs suppressed *VMA5* expression, leading to impaired V-ATPase and subsequent inhibition of acidification. This is summarized schematically in [Figure 9](#f9){ref-type="fig"}.

![Model of how inorganic arsenic (iAs) transforms prostate progenitor cells through NRF2 activation via autophagic flux blockade.](ehp6471_f9){#f9}

Our transcriptome analysis and functional studies identified a novel mechanism underlying iAs-induced autophagic flux blockade. Upon iAs exposure, suppression of *VMA5* gene led to compromised V-ATPase function and lysosome acidification, inhibiting the lysosomal degradation step of autophagic flux. Conversely, overexpression of *VMA5* partially attenuated iAs-induced p62 accumulation and NRF2 activation. Although VMA5 knockdown has been linked with attenuated Wnt signaling by impairing V-ATPase mediated acidification ([@c13]), the present study provides direct evidence for an essential role of VMA5 in V-ATPase function and autophagic flux regulation in mammal cells. V-ATPase has recently been implicated in various additional roles independent of its proton pump ability ([@c35]). Whether these noncanonical functions, which include endocytic traffic, metabolic sensing, and cell signaling, are affected by iAs are areas for potential exploration.

As a multidomain protein, p62 is a signaling hub linking autophagy and tumorigenesis. Downstream effectors of p62 determine its oncogenic or antioncogenic role in a context-dependent way ([@c27]; [@c40]; [@c53]). In this study, we demonstrated that NRF2 is an oncogenic effector of p62 during iAs-induced transformation. More important, we find that the status of the autophagic machinery of cells dictates the NRF2 responses upon iAs exposure, which may help to explain the controversial roles of autophagy in iAs-induced tumorigenesis ([@c45]). With high autophagy initiation and low VMA5 expression, progenitor cells have robust NRF2 activation upon iAs exposure, whereas it is limited in stem cells and differentiated epithelial cells due to lower autophagy initiation. Of significance is that iAs-induced NRF2 activation of progenitor cells is sustained in their differentiated progeny cells, which sets the stage for propagation of transformed cells and predisposition to a carcinogenic state.

Additionally, the phosphorylation status of p62 determines its downstream pathways. Phosphorylation of S349 (S351 for mouse) on the KIR domain activates the KEAP1-NRF2 pathway ([@c25]), whereas phosphorylation of S403 on the UBA domain regulates clearance of ubiquitinated proteins through autophagy ([@c34]). A recent study shows that T269/S272 phosphorylation is critical for amino acid activation of mTORC1 by p62 ([@c32]). Herein, we demonstrated that iAs-induced S349 phosphorylation of p62 leads to constitutive NRF2 activation in PrSPCs. Whether other modifications of p62 occur in these cells upon iAs exposure is currently unclear. NF-KB, beta-catenin, and ERK1 pathways are known downstream effectors of p62 and are also dysregulated by arsenic in other systems ([@c22]; [@c27]; [@c70]; [@c72]), and these effectors will be interrogated in future studies.

NRF2 and ROS have been shown to involved in iAs-induced tumorigenesis. Acute high-dose iAs ($> 5\;\mu M$) activates NRF2 and produces ROS ([@c41]; [@c71]) in mammary epithelial cells and keratinocytes ([@c41]; [@c53]; [@c71]), whereas chronic low-dose iAs ($< 1\;\mu M$) inhibits autophagic flux in differentiated cells (such as fibroblast, kidney, and lung epithelial cells), leading to noncanonical NRF2 activation and reduced ROS levels ([@c29]; [@c56]; [@c76]). In the current study, we demonstrated for the first time in prostate progenitor cells that low-dose iAs induces constant NRF2 activation through autophagic flux blockade. As a master transcription factor for cell defense and survival, NRF2 activates antioxidative and antiapoptotic pathways, facilitates iAs-transformed cell survival of microenvironmental stress, and increases tumor growth and metastasis ([@c26]; [@c56]; [@c76]). Indeed, we demonstrated that iAs-induced NRF2 activation attenuated inducive ROS generation, which may grant a survival advantage to iAs-transformed PrSPCs, allowing accumulation of tumorigenic events.

Recently, the role of NRF2 in iAs-induced malignant transformation has been linked with stem cells through reprogramming lung epithelial cells *in vitro* to form cancer stem-like cells ([@c6]). In our study, we extended the role for NRF2 in iAs tumorigenesis to dysregulation of human PrSPCs homeostasis though progenitor cells. iAs has been shown to target the stem cell populations during malignant transformation of WPE-stem cells, which is derived from immortalized RWPE1 cells ([@c64]). However, given the properties of rapid growth and high KRT14 expression ([@c61]), we propose that the majority of WPE-stem cells are progenitor rather than quiescent tissue stem cells. In this regard, observations from both cell lines and primary cells indicate that progenitor cells are major targets of iAs tumorigenesis in the prostate. This finding raises the possibility that iAs-induced prostate cancer may arise from progenitor cell dysregulation.

Mounting evidence suggests that dysregulation of progenitor cells is associated with tumorigenesis. In a classical stem cell--progenitor cell--committed cell hierarchy model, progenitor cells serve as a fast lane linking stem cells with differentiated progeny, as they rapidly proliferate, lineage commit, and form the bulk of tissue ([@c47]; [@c79]). These unique properties of progenitor cells make them vulnerable targets during tumorigenesis. Multipotent progenitor cells generated from infrequent divisions of hematopoietic stem cells can be transformed, leading to acute myeloid lymphoma ([@c30]). In addition, progenitor cells are physically close to stem cells, regulating both the stem cells and their niche. Accumulation of progenitor cells from intestinal stem cells by blocking their differentiation is sufficient to drive tumorigenesis in adult *Drosophila*. During this process, progenitor cells generate a feed-forward loop promoting stem cell proliferation and remodeling the stem cell environment ([@c10]; [@c78]). In the present study, suppression of NRF2 activation in RWPE-derived progenitor cells by NRF2 shRNA knockdown attenuated their transformation upon iAs exposure, which is in agreement with previous studies showing that blockade of persistent NRF2 activation mitigates iAs-induced transformation in lung epithelial cells ([@c56]; [@c76]). Further, we demonstrate that NRF2 activation leads to both enhanced progenitor self-renewal and decreased differentiation. Together this supports the central role of prostate progenitor cells in iAs tumorigenesis.

Although prostate cancer arises from epithelial cells, the stroma has been increasingly recognized as an important contributor for prostate tumorigenesis and progression ([@c4]). In the current *in vivo* study using a chimeric gland regeneration model, iAs activated the p62-NRF2 pathway in both epithelial and stromal cells. Recently, in a prostate cancer cell--conditioned media model, conditioned media from iAs-treated adipose-derived mesenchymal stem/stromal cells increased prostate tumor cell viability ([@c54]), and cytokine array analysis revealed that iAs increased HMOX1 expression but suppressed $\text{TGF-}\beta$ pathway activation in mesenchymal stem/stromal cells. Interestingly, in contrast to a tumorigenic role in epithelial cells, stromal p62 plays a protective role in prostate cancer progression by modulating metabolism in the tumor stroma ([@c31]; [@c67]). Thus, iAs may also affect PrSPCs indirectly through stromal microenvironment.

Although iAs induced transformation *in vitro*, we observed only a pre-cancerous phenotype of PTEN suppression, high proliferation, and de-differentiation, but not transformation associated with iAs exposure *in vivo*. There are a few possible explanations for this discrepancy. First, compared with lifelong iAs exposure, 3 months of iAs exposure may not be sufficient for full transformation of normal human PrSPCs derived from young donors. Second, elevated p62 expression in stroma by iAs may suppress tumorigenesis of epithelial cells as previously revealed ([@c31]; [@c67]). Further, the iAs metabolism in humans is different from that in mouse. Monomethylarsonic acid (MMA) is significantly more toxic than either iAs or the other metabolites, and humans have significantly higher MMA metabolite levels than most mammals have, including mice ([@c57]).

Just as iAs affects multiple organs, multiple signaling pathways are dysregulated by iAs as demonstrated in [Figure 2B,C](#f2){ref-type="fig"} and previous studies ([@c5]; [@c8]; [@c65]). Although we focused on NRF2 activation through autophagy dysregulation, other iAs-affected pathways may crosstalk with NRF2 pathway as well. Oncogenic KRAS, which was also up-regulated in iAs-treated PrSPCs ([Figure 2C](#f2){ref-type="fig"}), has been reported to directly increase NRF2 gene transcription in lung cancer cells through a TPA response element located in the NRF2 promoter ([@c60]). Although NRF2 mRNA was not affected by iAs in day-7 PrSPCs ([Figure 2E](#f2){ref-type="fig"}), KRAS may activate NRF2 in daughter cells of PrSPCS over time. It has been shown that p53 counteracts NRF2-induced transcription through direct interaction with NRF2-binding sites of promoters ([@c15]). As shown in [Figure 2C](#f2){ref-type="fig"}, iAs suppressed p53 in PrSPCs as well, which may contribute to NRF2 activation in the context of p62 knockdown ([Figure 4C](#f4){ref-type="fig"}). How iAs affects oncogenic pathways ([Figure 2B,C](#f2){ref-type="fig"}) cross-talk with each other will be actively explored in future studies.

Conclusion {#s6}
==========

In summary, we outlined a novel mechanism by which iAs disturbs homeostasis of PrSPCs and predisposes to tumorigenesis. This work adds to knowledge of both iAs toxicology and prostate cancer, linking a novel role for NRF2 in PrSPC regulation. In addition to demonstrating that iAs activates NRF2 through autophagic flux blockade in prostate progenitor cells, this work reveals a unique molecular mechanism by which iAs inhibits lysosomal degradation via suppression of V-ATPase function. Further, we demonstrate for the first time, to our knowledge, the dynamics of autophagy in prostate epithelial cells during stem cell differentiation and find the autophagic status of these cell populations determines their NRF2 responses to iAs exposure. Our findings support the hypothesis that transient amplifying prostate progenitors are primary iAs targets and that iAs exposure may lead to their accumulation and transformation by increasing self-renewal and inhibiting differentiation through NRF2 activation. As such, this work sheds light on the potential for rational development of novel strategies targeting autophagy to mitigate adverse effects of iAs and for therapeutic approaches of prostate cancer.
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